p16 inactivation was the major mechanism of RB pathway perturbation in non-small-cell lung carcinoma, with homozygous deletion being the most frequent method, followed by methylation and the rarer point mutations (Tam et al., 2013). Here, RB1 is linked to non-small cell lung carcinoma.